ALAlphabet Inc.

Institutional investor · Portfolio as of Q3 2023

SEC EDGAR SourceSEC Filings

Top Holdings45 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

UIPATH INC

14.1M$240.7M15.5%$12.71+34.62%
4 qtrssince 2022-Q4
Unchanged
0

CROWDSTRIKE HOLDINGS INC - A

1.3M$214.9M13.8%$120.06+39.41%
4 qtrssince 2022-Q4
Unchanged
0
VERVVERVDelisted

VERVE THERAPEUTICS INC

10.5M$139.9M9.0%
4 qtrssince 2022-Q4
Unchanged
0

GITLAB INC

2.6M$119.7M7.7%$43.53+3.88%
4 qtrssince 2022-Q4
Unchanged
0

PRIME MEDICINE INC

11.9M$113.2M7.3%$18.58-48.65%
4 qtrssince 2022-Q4
Unchanged
0
EQRXEQRXDelisted

EQRx Inc.

47.7M$105.8M6.8%
4 qtrssince 2022-Q4
Unchanged
0
ARMARM
ADR

ARM Holdings PLC Sponsored ADR

2M$104.9M6.7%$53.520.00%
1 qtr
New
94

PLANET LABS PBC

31.9M$83.1M5.3%$4.35-40.23%
4 qtrssince 2022-Q4
Unchanged
0

SNOWFLAKE INC-CLASS A

535,604$81.8M5.3%$143.54+6.43%
4 qtrssince 2022-Q4
Unchanged
0

OSCAR HEALTH INC - CLASS A

14.5M$80.6M5.2%$2.46+126.42%
4 qtrssince 2022-Q4
Decreased
0

FRESHWORKS INC

4M$80.4M5.2%$14.71+35.42%
4 qtrssince 2022-Q4
Unchanged
0

DEXCOM INC

654,854$61.1M3.9%$113.24-17.61%
4 qtrssince 2022-Q4
Decreased
0
DMDMDelisted

Desktop Metal Inc.

11M$16.1M1.0%

RELAY THERAPEUTICS INC

1.6M$13.2M0.8%$14.94-43.71%
4 qtrssince 2022-Q4
Unchanged
0

SANA BIOTECHNOLOGY INC

2.8M$10.9M0.7%$3.95-2.03%
4 qtrssince 2022-Q4
Unchanged
0

INVIVYD INC

5.7M$9.7M0.6%$1.50+13.33%
4 qtrssince 2022-Q4
Unchanged
0
RAPTRAPTDelisted

RAPT Therapeutics Inc.

540,270$9M0.6%

LYELL IMMUNOPHARMA INC

5.9M$8.6M0.6%

BEAM THERAPEUTICS INC

321,604$7.7M0.5%$39.11-38.51%
4 qtrssince 2022-Q4
Unchanged
0

ILLUMINA INC

53,470$7.3M0.5%$196.69-32.11%
4 qtrssince 2022-Q4
Unchanged
0
$1.6B
AUM
45
Positions
Q3 2023
Filing
Rating · 2.0
Quarterly Portfolio Change
+5%Q1'23$1.8B+3%Q2'23$1.9B-16%Q3'23$1.6B
Activity profile
$ moved · Q3'23
New30%Increased0%Decreased56%Exited14%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.3 quarters
<1Q7%1-4Q84%1-2Y0%2Y+9%

Alphabet Inc. manages $1.6B across 45 positions as of Q3 2023. Top holdings: PATH (15.5%), CRWD (13.8%), VERV (9.0%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 2/5.0.

Q3 2023 Summary

Added 3 new positions, exited 5, trimmed 2. Top move: ARM (NEW, conviction 94). Portfolio: $1.6B across 45 positions.

Top holdings by portfolio weight

Total AUM$2B
PATH15.46%
CRWD13.80%
VERV8.98%
GTLB7.69%
PRME7.27%
EQRX6.80%
ARM6.74%
PL5.33%
SNOW5.26%
OSCR5.18%
Other5.16%

Portfolio allocation by GICS sector

Sectors4
Technology54.11%
Healthcare23.20%
Unknown17.36%
Industrials5.33%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Technology, Healthcare, Unknown
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track RecordNo data
Conviction37
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used